Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey. Show more
Location: Cedar Brook Corporate Center, Cranbury, NJ, 08512, United States | Website: https://palatin.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
2.447M
52 Wk Range
$0.04 - $2.13
Previous Close
$0.17
Open
$0.10
Volume
14,571,856
Day Range
$0.09 - $0.11
Enterprise Value
-611.7K
Cash
3.417M
Avg Qtr Burn
-6.736M
Insider Ownership
2.63%
Institutional Own.
14.22%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Vyleesi® (bremelanotide) MC4r Agonist Details Sexual dysfunction, Sexual desire disorder, Influenza | Approved Quarterly sales | |
PL9643 Details Dry eye syndrome | Phase 3 Update | |
Bremelanotide + PDE5i Details Erectile dysfunction
| Phase 2 Data readout | |
PL8177 oral formulation Details Chronic inflammatory disorder, Inflammatory disease, Bowel disorder, Ulcerative colitis | Phase 2 Update | |
Bremelanotide Details Diabetic Kidney Disease | Phase 2 Update | |
Bremelanotide + Tirzepatide Details Obesity, Metabolic disorder | IND Submission | |
PL8177 Details Eye disease , Inflammatory disease | Failed Discontinued | |
PL3994 (NPR-A agonist) Details Heart disease | Failed Discontinued | |
PL8177 Details COVID-19 | Failed Discontinued |